Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Clinical trial NCT05112159 · COMPLETED
Trial details
- NCT number
- NCT05112159
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-27
- Primary completion
- 2022-07-25
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.